ASCO 2004 Annual Meeting: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
 

ASCO 2004 Symposium GI Sarcoma Update: ACTIVITY AND TOLERABILITY OF THE MULTI-TARGETED TYROSINE KINASE INHIBITOR SU011248 IN PATIENTS (PTS) WITH METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) REFRACTORY TO IMATINIB MESYLATE
 

Targeting the KIT Tyrosine Kinase with STI571 (Gleevec, Imatinib meslylate) in Solid Tumors: Getting the GIST of It